ES2878078T3 - Inhibidores de GSK-3 - Google Patents
Inhibidores de GSK-3 Download PDFInfo
- Publication number
- ES2878078T3 ES2878078T3 ES17812188T ES17812188T ES2878078T3 ES 2878078 T3 ES2878078 T3 ES 2878078T3 ES 17812188 T ES17812188 T ES 17812188T ES 17812188 T ES17812188 T ES 17812188T ES 2878078 T3 ES2878078 T3 ES 2878078T3
- Authority
- ES
- Spain
- Prior art keywords
- carboxamide
- yield
- esi
- pyrimidine
- calc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YMDSUQSBJRDYLI-UHFFFAOYSA-N OC(c1nc(Cl)ncc1)=O Chemical compound OC(c1nc(Cl)ncc1)=O YMDSUQSBJRDYLI-UHFFFAOYSA-N 0.000 description 2
- XTXBJSSLCXAFJR-UHFFFAOYSA-N CC(C)(C)C(CC1)CCC1Nc1nccc(C(Nc(cncc2)c2OCC(F)(F)F)=O)n1 Chemical compound CC(C)(C)C(CC1)CCC1Nc1nccc(C(Nc(cncc2)c2OCC(F)(F)F)=O)n1 XTXBJSSLCXAFJR-UHFFFAOYSA-N 0.000 description 1
- HTCKPIPTJXFOFT-UHFFFAOYSA-N CC(C)(C)CNc1nccc(C(Nc2cncnc2N2CCOCC2)=O)n1 Chemical compound CC(C)(C)CNc1nccc(C(Nc2cncnc2N2CCOCC2)=O)n1 HTCKPIPTJXFOFT-UHFFFAOYSA-N 0.000 description 1
- WLQOXZNFGHTEIE-UHFFFAOYSA-N CC(C)(C1)N(C)C(C)(C)CC1Nc1nccc(C(Nc2cnccc2OCC(F)(F)F)=O)n1 Chemical compound CC(C)(C1)N(C)C(C)(C)CC1Nc1nccc(C(Nc2cnccc2OCC(F)(F)F)=O)n1 WLQOXZNFGHTEIE-UHFFFAOYSA-N 0.000 description 1
- VIAZLHXPEDETQB-UHFFFAOYSA-N CC(C)CNc(cc1)ncc1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 Chemical compound CC(C)CNc(cc1)ncc1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 VIAZLHXPEDETQB-UHFFFAOYSA-N 0.000 description 1
- WUKGCRFHSIOYOX-UHFFFAOYSA-N CC(Nc(cc1)ncc1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1)=O Chemical compound CC(Nc(cc1)ncc1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1)=O WUKGCRFHSIOYOX-UHFFFAOYSA-N 0.000 description 1
- XVQHINAUKDETSJ-UHFFFAOYSA-N CC1(CNc2nccc(C(Nc3cncnc3OCC(F)(F)F)=O)n2)COC1 Chemical compound CC1(CNc2nccc(C(Nc3cncnc3OCC(F)(F)F)=O)n2)COC1 XVQHINAUKDETSJ-UHFFFAOYSA-N 0.000 description 1
- FXJJAFJKCUZEHZ-UHFFFAOYSA-N CCCC1(c(cc(nc2)Cl)c2NC(c2nc(NC3CCOCC3)ncc2)=O)OCCO1 Chemical compound CCCC1(c(cc(nc2)Cl)c2NC(c2nc(NC3CCOCC3)ncc2)=O)OCCO1 FXJJAFJKCUZEHZ-UHFFFAOYSA-N 0.000 description 1
- WMICVOFUIXJEAJ-KFBSOOBASA-N CCO[C@@H](COC1)/C1=N\c1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 Chemical compound CCO[C@@H](COC1)/C1=N\c1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 WMICVOFUIXJEAJ-KFBSOOBASA-N 0.000 description 1
- XUFGGBMPYWYXBH-UHFFFAOYSA-N CN(C)c(cc1)ncc1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 Chemical compound CN(C)c(cc1)ncc1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 XUFGGBMPYWYXBH-UHFFFAOYSA-N 0.000 description 1
- VYGKCRISLZAKIV-UHFFFAOYSA-N CNc1nccc(C(Nc(cncc2)c2OCC(F)(F)F)=O)n1 Chemical compound CNc1nccc(C(Nc(cncc2)c2OCC(F)(F)F)=O)n1 VYGKCRISLZAKIV-UHFFFAOYSA-N 0.000 description 1
- RGHXAJODEWEBHG-UHFFFAOYSA-N COc1cc(C2C(CNc3nccc(C(Nc4cncnc4)=O)n3)C2)ccc1 Chemical compound COc1cc(C2C(CNc3nccc(C(Nc4cncnc4)=O)n3)C2)ccc1 RGHXAJODEWEBHG-UHFFFAOYSA-N 0.000 description 1
- NRSNSOCDKWGUMR-UHFFFAOYSA-N C[n](cc1)nc1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 Chemical compound C[n](cc1)nc1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 NRSNSOCDKWGUMR-UHFFFAOYSA-N 0.000 description 1
- LYVOHPYWGZFHPE-UHFFFAOYSA-N Cc(cc(cc1)C#N)c1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 Chemical compound Cc(cc(cc1)C#N)c1Nc1nccc(C(Nc(cncc2)c2-c2ccccc2)=O)n1 LYVOHPYWGZFHPE-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1cc(Nc2nccc(C(Nc(cncc3)c3-c3ccccc3)=O)n2)c(C)nc1* Chemical compound Cc1cc(Nc2nccc(C(Nc(cncc3)c3-c3ccccc3)=O)n2)c(C)nc1* 0.000 description 1
- JSCZAIGVEGNKJG-UHFFFAOYSA-N Nc(cncc1)c1OCC(F)(F)F Chemical compound Nc(cncc1)c1OCC(F)(F)F JSCZAIGVEGNKJG-UHFFFAOYSA-N 0.000 description 1
- CUYKNJBYIJFRCU-UHFFFAOYSA-N Nc1cnccc1 Chemical compound Nc1cnccc1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
- MICXXDDFHWQPBI-UHFFFAOYSA-N O=C(c1nc(Cl)ncc1)Nc(cncc1)c1OCC(F)(F)F Chemical compound O=C(c1nc(Cl)ncc1)Nc(cncc1)c1OCC(F)(F)F MICXXDDFHWQPBI-UHFFFAOYSA-N 0.000 description 1
- AVLIJFIZRRCPLE-UHFFFAOYSA-N O=C(c1nc(Cl)ncc1)Nc1cnccc1 Chemical compound O=C(c1nc(Cl)ncc1)Nc1cnccc1 AVLIJFIZRRCPLE-UHFFFAOYSA-N 0.000 description 1
- HQQIIVBXUSWTDM-IURRXHLWSA-N O=C(c1nc(NC(C2)[C@H]2c2ccccc2)ncc1)Nc1cncnc1 Chemical compound O=C(c1nc(NC(C2)[C@H]2c2ccccc2)ncc1)Nc1cncnc1 HQQIIVBXUSWTDM-IURRXHLWSA-N 0.000 description 1
- YREUQQBSQQKHBD-UHFFFAOYSA-N O=C(c1nc(NC2CCOCC2)ncc1)Nc(c(N(CC1)CCC1(F)F)c1)cnc1F Chemical compound O=C(c1nc(NC2CCOCC2)ncc1)Nc(c(N(CC1)CCC1(F)F)c1)cnc1F YREUQQBSQQKHBD-UHFFFAOYSA-N 0.000 description 1
- IKSZFKZIEJUTJI-UHFFFAOYSA-N O=C(c1nc(NCC(C2)C2c(cc2)ccc2F)ncc1)Nc1cncnc1 Chemical compound O=C(c1nc(NCC(C2)C2c(cc2)ccc2F)ncc1)Nc1cncnc1 IKSZFKZIEJUTJI-UHFFFAOYSA-N 0.000 description 1
- HPVUJMBMOFRVHJ-UHFFFAOYSA-N O=C(c1nc(NCC(C2)C2c(ccc(F)c2)c2F)ncc1)Nc1cncnc1 Chemical compound O=C(c1nc(NCC(C2)C2c(ccc(F)c2)c2F)ncc1)Nc1cncnc1 HPVUJMBMOFRVHJ-UHFFFAOYSA-N 0.000 description 1
- QAUGUMLVQAXECZ-UHFFFAOYSA-N O=C(c1nc(NCC(C2)C2c2cccc(F)c2)ncc1)Nc1cncnc1 Chemical compound O=C(c1nc(NCC(C2)C2c2cccc(F)c2)ncc1)Nc1cncnc1 QAUGUMLVQAXECZ-UHFFFAOYSA-N 0.000 description 1
- SEZUHNRHUXEVPK-UHFFFAOYSA-N O=C(c1nc(NCC2CC2)ncc1)Nc(cncn1)c1OCC(F)(F)F Chemical compound O=C(c1nc(NCC2CC2)ncc1)Nc(cncn1)c1OCC(F)(F)F SEZUHNRHUXEVPK-UHFFFAOYSA-N 0.000 description 1
- AIUFVBSOOVLPOG-UHFFFAOYSA-N O=C(c1nc(NCc(cc2)ccc2F)ncc1)Nc1cnccc1OCC(F)(F)F Chemical compound O=C(c1nc(NCc(cc2)ccc2F)ncc1)Nc1cnccc1OCC(F)(F)F AIUFVBSOOVLPOG-UHFFFAOYSA-N 0.000 description 1
- JYUKYRFXLNRVHT-UHFFFAOYSA-N O=C(c1nc(NCc2ccccc2)ncc1)Nc(cncc1)c1OCC(F)(F)F Chemical compound O=C(c1nc(NCc2ccccc2)ncc1)Nc(cncc1)c1OCC(F)(F)F JYUKYRFXLNRVHT-UHFFFAOYSA-N 0.000 description 1
- LCFWIKUBJZHUBF-UHFFFAOYSA-N O=C(c1nc(Nc(cc2)ccc2Cl)ncc1)Nc(c(N(CC1)CCC1(F)F)c1)cnc1F Chemical compound O=C(c1nc(Nc(cc2)ccc2Cl)ncc1)Nc(c(N(CC1)CCC1(F)F)c1)cnc1F LCFWIKUBJZHUBF-UHFFFAOYSA-N 0.000 description 1
- MLBFCSJJRVBMRM-UHFFFAOYSA-N O=C(c1nc(Nc(cc2)ccc2OC(F)(F)F)ncc1)Nc(cncc1)c1-c1ccccc1 Chemical compound O=C(c1nc(Nc(cc2)ccc2OC(F)(F)F)ncc1)Nc(cncc1)c1-c1ccccc1 MLBFCSJJRVBMRM-UHFFFAOYSA-N 0.000 description 1
- KCHZWTYLVBPEHB-UHFFFAOYSA-N O=C(c1nc(Nc(cc2)ccc2OC(F)(F)F)ncc1)Nc1cnccc1-c(cc1)ccc1F Chemical compound O=C(c1nc(Nc(cc2)ccc2OC(F)(F)F)ncc1)Nc1cnccc1-c(cc1)ccc1F KCHZWTYLVBPEHB-UHFFFAOYSA-N 0.000 description 1
- LQUOZMWMVKGGPP-UHFFFAOYSA-N O=C(c1nc(Nc(ccc(F)c2)c2F)ncc1)Nc(cncc1)c1-c(ccc(F)c1)c1F Chemical compound O=C(c1nc(Nc(ccc(F)c2)c2F)ncc1)Nc(cncc1)c1-c(ccc(F)c1)c1F LQUOZMWMVKGGPP-UHFFFAOYSA-N 0.000 description 1
- FTEMAKWBAPQZQY-UHFFFAOYSA-N O=C(c1nc(Nc2ccccn2)ncc1)Nc(cncc1)c1-c(cc1)ccc1F Chemical compound O=C(c1nc(Nc2ccccn2)ncc1)Nc(cncc1)c1-c(cc1)ccc1F FTEMAKWBAPQZQY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426631P | 2016-11-28 | 2016-11-28 | |
| PCT/US2017/063231 WO2018098412A1 (en) | 2016-11-28 | 2017-11-27 | Gsk-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2878078T3 true ES2878078T3 (es) | 2021-11-18 |
Family
ID=60655130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17812188T Active ES2878078T3 (es) | 2016-11-28 | 2017-11-27 | Inhibidores de GSK-3 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10752609B2 (enExample) |
| EP (1) | EP3544613B1 (enExample) |
| JP (1) | JP7114591B2 (enExample) |
| KR (1) | KR102575990B1 (enExample) |
| CN (1) | CN110545817B (enExample) |
| ES (1) | ES2878078T3 (enExample) |
| MA (1) | MA46889A (enExample) |
| WO (1) | WO2018098412A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018098413A1 (en) * | 2016-11-28 | 2018-05-31 | Bristol-Myers Squibb Company | Pyrimidine carboxamides as gsk-3 inhibitors |
| MA54546A (fr) * | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| JP7676308B2 (ja) | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| AU2020324406A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| CN116178281B (zh) * | 2023-04-27 | 2023-07-21 | 中国药科大学 | 一种双功能免疫抑制剂及其制备方法和应用 |
| TW202509014A (zh) * | 2023-05-10 | 2025-03-01 | 美商纜圖藥品公司 | GSK3α抑制劑及其使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| CN101801958B (zh) * | 2007-07-19 | 2014-01-29 | 默沙东公司 | 作为蛋白质激酶抑制剂的杂环酰胺化合物 |
| WO2012024179A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| SG11201603209XA (en) * | 2013-11-06 | 2016-05-30 | Bristol Myers Squibb Co | Gsk-3 inhibitors |
| AU2014347026A1 (en) * | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | Substituted pyridine derivatives useful as GSK-3 inhibitors |
| WO2016144797A1 (en) * | 2015-03-06 | 2016-09-15 | Alpharmagen, Llc | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| WO2018098413A1 (en) * | 2016-11-28 | 2018-05-31 | Bristol-Myers Squibb Company | Pyrimidine carboxamides as gsk-3 inhibitors |
-
2017
- 2017-11-27 MA MA046889A patent/MA46889A/fr unknown
- 2017-11-27 US US16/463,467 patent/US10752609B2/en active Active
- 2017-11-27 CN CN201780084344.7A patent/CN110545817B/zh active Active
- 2017-11-27 EP EP17812188.5A patent/EP3544613B1/en active Active
- 2017-11-27 JP JP2019528512A patent/JP7114591B2/ja active Active
- 2017-11-27 ES ES17812188T patent/ES2878078T3/es active Active
- 2017-11-27 KR KR1020197018285A patent/KR102575990B1/ko active Active
- 2017-11-27 WO PCT/US2017/063231 patent/WO2018098412A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN110545817A (zh) | 2019-12-06 |
| CN110545817B (zh) | 2022-11-15 |
| US20190315714A1 (en) | 2019-10-17 |
| JP7114591B2 (ja) | 2022-08-08 |
| EP3544613B1 (en) | 2021-06-09 |
| KR102575990B1 (ko) | 2023-09-08 |
| MA46889A (fr) | 2019-10-02 |
| EP3544613A1 (en) | 2019-10-02 |
| JP2019535788A (ja) | 2019-12-12 |
| WO2018098412A1 (en) | 2018-05-31 |
| US10752609B2 (en) | 2020-08-25 |
| KR20190085114A (ko) | 2019-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2878078T3 (es) | Inhibidores de GSK-3 | |
| KR102030305B1 (ko) | 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물 | |
| CA2863515C (en) | Pyridone derivatives | |
| ES2536479T3 (es) | Derivados de la piridina y la pirazina como moduladores de la proteína quinasa | |
| AU2015313782B2 (en) | Compounds and compositions as RAF kinase inhibitors | |
| KR102339227B1 (ko) | Gsk-3 억제제 | |
| BR112020026748A2 (pt) | Inibidores de quinases dependentes de ciclina | |
| RU2692479C2 (ru) | (5,6-дигидро)пиримидо[4,5-е]индолизины | |
| KR102292433B1 (ko) | Gsk-3 억제제로서 유용한 치환된 피리딘 유도체 | |
| CN104837829A (zh) | 抑制剂化合物 | |
| IL296265A (en) | Fused pyrimidine compounds as kcc2 modulators | |
| EP3694330B1 (en) | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| AU2017208555A1 (en) | New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | |
| CN104837844A (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
| CA2630360A1 (en) | Substituted bicyclic pyrimidone derivatives | |
| ES2896938T3 (es) | Inhibidores de GSK-3 | |
| KR20240047371A (ko) | Cd38 조절제 및 이의 사용 방법 |